Is it okay to lose 450 in one dose of trastuzumab?

Fam-trastuzumab deruxtecan-nxki is a drug used to treat HER2-positive breast cancer (MBC), non-small cell lung cancer (NSCLC), and gastric cancer (MGC). When patients start taking trastuzumab, they need to undergo corresponding genetic mutation and tumor sample testing. According to the drug instructions, the recommended dose for patients with breast cancer and non-small cell lung cancer is 5.4 mg/kg by intravenous injection every 3 weeks, and the recommended dose for patients with gastric cancer is 6.4 mg/kg. Therefore, the specific infusion dose should be determined based on the patient's weight.

In clinical trials and practical applications, there is usually a standard dosing regimen as a reference, but this does not mean that every patient should receive the same dose. If the dose is calculated as 450mg, the patient's weight needs to be known and the appropriate dose can be calculated based on the weight. For example, if the patient weighs 50kg, then 450mg would be equivalent to a dose of 9mg/kg, which may be a reasonable dose. If the patient's medical condition, severity of illness, or other factors make this dose unsafe or inappropriate, the doctor may adjust the dose or choose an alternative treatment.

In short, the dosage of trastuzumab is a matter that requires individual consideration. Patients should follow the doctor's advice and guidance and do not adjust the dosage or change the medication regimen on their own. Do not substitutetrastuzumab or ado-trastuzumab emtansine. During the treatment process, patients should pay close attention to their physical condition and communicate with the doctor in a timely manner in order to adjust the treatment plan and obtain the best treatment effect.